Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole

Annals of Oncology

Volumn 10, Issue 7, 1999, Pages 809-815

  Cottin, V ^a,c   Arpin, D ^d   Lasset, C ^d   Cordier, J F ^d   Brune, J ^d   Chauvin, F ^d   Trillet Lenoir, V ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d NONE

Author keywords

Clinical trials; Eligibility; Small cell lung cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MESNA; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; CLINICAL TRIALS; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032793404     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008399831512     Document Type: Article

References (33)

1. Collet JP, Boissel JP. Sick population-treated population: The need for a better definition. The VALIDATA Group. Eur J Clin Pharmacol 1991; 41: 267-71.
2. Antman K, Amato D, Wood W et al. Selection bias in clinical trials, J Clin Oncol 1985; 3: 1142-7.
3. McCuster J, Wax A, Bennett JM. Cancer patient accessions into clinical trials: A pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol 1982; 5: 227-36.
4. Lee JY, Breaux SR. Accrual of radiotherapy patients to clinical trials. Cancer 1983; 52: 1014-6.
5. Lee JY, Marks JE, Simpson JR. Age as a criterion for eligibility in a lung cancer clinical trial. Cancer Clin Trials 1982; 5: 449-52.
6. Allan SG, Stewart ME, Love S et al. Prognosis at presentation of small-cell carcinoma of the lung. Eur J Cancer 1990; 26: 703-5.
7. Quoix E, Finkelstein H, Wolkove N, Kreisman H. Treatment of small-cell lung cancer on protocol: Potential bias of results. J Clin Oncol 1986; 4: 1314-20.
8. Trillet-Lenoir V, Mornex F, Chauvin F et al. Limited disease small-cell lung cancer: Alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Lung Cancer 1993; 10: 35-45.
9. Mornex F, Trillet V, Chauvin F, et al. Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 1990; 19: 23-30.
10. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 3: 319-24.
11. Jarry O, Fournel P, for the Groupe Lyonnais d'Oncologie Thoracique. A randomized trial of four versus eight courses of chemotherapy with ifosfamide, epirubicin and etoposide in extensive small-cell lung cancer. Proceedings of the Seventh World Conference on Lung Cancer 1996; 14 (Abstr 387).
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
13. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187-220.
14. Barofsky I, Sugarbaker PH. Determinants of patient non-participation in randomized clinical trials for the treatment of sarcomas. Cancer Clin Trials 1979; 2: 237-46.
15. Goodwin JS, Hunt WC, Humble CG et al. Cancer treatment protocols. Who gets chosen? Arch Intern Med 1988; 148: 2258-60.
16. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-5.
17. Taylor KM, Margolese RG, Soskolne CL. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 1984; 310: 1363-7.
18. Simes RJ, Tattersall MH, Coates AS et al. Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J 1986; 293: 1065-8.
19. Fost N. Consent as a barrier to research. N Engl J Med 1979; 300: 1272-3.
20. Rawson NS, Peto J. An overview of prognostic factors in small-cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597-604.
21. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: Why so badly treated? Lancet 1990; 335: 1020-2.
22. Négrier S, Lanier-Demma F, Lacroix-Kante V et al. Evaluation of the informed consent procedure in cancer patients candidate to immunotherapy. Eur J Cancer 1995; 31A: 1650-2.
23. Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Information and participation preferences among cancer patients. Ann Intern Med 1980; 92: 832-6.
24. Johnson BE. Management of small-cell lung cancer. Clin Chest Med 1993; 14: 173-87.
25. Darling GE. Staging of the patient with small-cell lung cancer. Chest Surg Clin N Am 1997; 7: 81-94.
26. Chauvin F, Trillet V, Court-Fortune I et al. Pre-treatmenl staging evaluation in small-cell lung carcinoma. A new approach to medical decision making. Chest 1992; 102: 497-502.
27. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46: 4189-94.
28. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563-74.
29. Ihde DC, Makuch RW, Carney DN et al. Prognostic implications of stage of disease and sites of metastases in patients with small-cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 1981; 123: 500-7.
30. Gronowitz JS, Bergstrom R, Nou E et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990; 66; 722-32.
31. Spiegelman D, Maurer LH, Ware JH et al. Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 1989; 7: 344-54.
32. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: Derivation of a prognostic staging system. J Clin Oncol 1991; 9: 1639-49.
33. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989; 299: 1069-72.